Navigation Links
Bioheart Announces 35 Leading U.S. Heart Failure Centers Engaged in Phase II/III Marvel Trial of Myogenic Cells for Treating Advanced Heart Failure
Date:9/30/2008

proval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its lead product candidate, MyoCell(R), is an innovative clinical muscle-derived stem cell therapy designed to populate regions of scar tissue within a patient's heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. The Company's pipeline includes multiple product candidates for the treatment of heart damage, including Bioheart Acute Cell Therapy, an autologous, adipose tissue-derived stem cell treatment for acute heart damage, and MyoCell(R) SDF-1, a therapy utilizing autologous cells that are genetically modified to express additional potentially therapeutic growth proteins. For more information on Bioheart, visit http://www.bioheartinc.com.

Footnotes:

(1) MARVEL: A Phase II/III, Double-Blind, Randomized, Placebo-Controlled Multi-center study to Assess the Safety and Cardiovascular Effects of MyoCell Implantation by a Catheter Delivery System in Congestive Heart Failure Patients Post-Myocardial Infarction(s)

(2) The MYOSTAR(TM) Injection Catheter is not available for sale in the U.S. It is in use in IND investigations

MyoCell and MyoCell SDF-1 are trademarks of Bioheart, Inc.

MyoStar and NOGA XP are trademarks of Cordis Corporation, a Johnson & Johnson company

Forward Looking Statements:

Except for historical matters contained herein, statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Without limiting the generality of the foregoing, words such as "may", "will", "to", "plan", "expect",

"believe", "anticipate", "intend", "could", "would", "estimate", or "continue" or the negative other variations thereof or comparable terminology are intended to identify forward-looking statements.
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
2. Bioheart Reports Promising Results From SDF-1 Modified MyoCell(R) Therapy in Heart Failure Study
3. Bioheart Reports Promising Results From Preclinical Study of Adipose-Derived Acute Cell Therapy
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
6. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
7. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
8. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
9. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
10. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
11. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 30, 2015  Astellas today announced topline results ... efficacy and safety of intravenous (IV) and oral ... development for adults with candidemia and other invasive ... demonstrated that the trial did not meet its ... in isavuconazole-treated patients at the end of IV ...
(Date:7/29/2015)... 2015 Insulet Corporation (NASDAQ: PODD ), ... OmniPod ® Insulin Management System, today announced preliminary ... 2015. The Company also announced that it will postpone ... and conference call from Thursday, July 30, as originally ... Highlights: , Preliminary second quarter ...
(Date:7/29/2015)... MONICA, Calif. , July 29, 2015  UBM ... the San Diego Marriott Marquis & Marina on September ... medical device industry. A highlight of the Business Development ... Financial Backing from Different Types of Investors, featuring ... & Johnson Development Corporation; Brent Ahrens , Partner, ...
Breaking Medicine Technology:Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 2Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 3Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 4Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 5Insulet Reports Preliminary Second Quarter 2015 Revenue Results 2Insulet Reports Preliminary Second Quarter 2015 Revenue Results 3Insulet Reports Preliminary Second Quarter 2015 Revenue Results 4Insulet Reports Preliminary Second Quarter 2015 Revenue Results 5MEDevice San Diego Offers Tips on Securing Financial Backing from Investors 2
... NEW YORK, Jan. 11, 2011 WebMD Health Corp. (Nasdaq: ... private placement of $400 million aggregate principal amount of 2.50% ... of notes pursuant to the exercise in full of the ... qualified institutional buyers pursuant to Rule 144A under the Securities ...
... /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems Ltd. (Nasdaq: ... in the development, assembly, marketing and sale of medical ... that it will participate in the Arab Health Exhibition ... 2011 at the Dubai World Trade Centre in Dubai, ...
Cached Medicine Technology:WebMD Closes Offering of 2.50% Convertible Notes Due 2018 2Dehaier Medical Announces Participation in Arab Health 2011 2
(Date:7/30/2015)... ... 2015 , ... PeopleKeys, a company with over 30 years of experience in ... The webinar, the newest installment in their popular DISC for the Real World series, ... the Trainer webinar is intended for people interested in training others to use DISC ...
(Date:7/30/2015)... ... July 30, 2015 , ... Addictions Training Institute ... for people to become Certified Alcohol and Substance Abuse Counselors. , "We are thrilled ... “There is an acute shortage of Alcohol and Drug Counselors nationwide. We ...
(Date:7/29/2015)... California (PRWEB) , ... July 30, 2015 , ... Avid ... Hendrix Dorton Arena Raleigh North Carolina concert posters. The same poster art was used ... printed by Globe Poster based in Baltimore and are classic boxing style concert posters. ...
(Date:7/29/2015)... , ... July 30, 2015 , ... ... for their clients, BOC approved provider of online continuing education courses for ... offerings to their exclusive Andrews Research and Education Sports Medicine Series. , The ...
(Date:7/29/2015)... ... July 29, 2015 , ... According to data released today by the ... is expected to remain stable at $32.50, a figure far lower than was originally ... continues to be a bright spot in American health care. By offering an abundance ...
Breaking Medicine News(10 mins):Health News:PeopleKeys to Air “Managing Stress: Train the Trainer” DISC Webinar 2Health News:Addictions Training Institute Announces New Online Certificate Program for Alcohol and Drug Counselors 2Health News:Elite Online Continuing Education Provider Adds Six New Athletic Training Courses to Exclusive Andrews Research and Education Sports Medicine Series 2Health News:Elite Online Continuing Education Provider Adds Six New Athletic Training Courses to Exclusive Andrews Research and Education Sports Medicine Series 3
... but often deadly disease that can strike at any time ... and in the past was referred to as a silent ... ovarian cancer that can assist in early detection. Experts at ... of preventive methods, understand the risks and recognize potential warning ...
... that the hormone estrogen may help reverse advanced pulmonary hypertension, ... million individuals in the U.S., mostly women, and can lead ... progressive increase in blood pressure in the main pulmonary artery, ... to the lungs. The rise in pressure impairs heart function ...
... By Steven Reinberg HealthDay Reporter , THURSDAY, ... increasing rates of drug-resistant tuberculosis, health officials say the disease ... least so far. But, they add, the ease of ... one should think they,re beyond risk. "Drug-resistant TB exists ...
... The demand for transparency through publicly available healthcare data ... and clinical data for research, and for clinical trials data ... a measurable impact on research and policy making. A new ... in Electronic Health Information at the University of Ottawa and ...
... spent glued to their PlayStation 3, Xbox 360 or Nintendo ... perhaps? Improved concentration? Superior driving skills? Over the past ... action video games such as Medal of Honor or Unreal ... in a paper published this week in the journal Frontiers ...
... HealthDay Reporter , WEDNESDAY, Sept. 14 (HealthDay News) ... jumped dramatically worldwide, from about 640,000 in 1980 to more ... Over the same period, the number of cases of ... from that cancer have declined, although in 2010 it still ...
Cached Medicine News:Health News:Early detection is key in the fight against ovarian cancer 2Health News:Early detection is key in the fight against ovarian cancer 3Health News:Estrogen treatment may help reverse severe pulmonary hypertension 2Health News:Estrogen treatment may help reverse severe pulmonary hypertension 3Health News:Officials Tackle Multidrug-Resistant TB in Europe 2Health News:Officials Tackle Multidrug-Resistant TB in Europe 3Health News:New report on creating clinical public use microdata files 2Health News:Put down that Xbox remote: FSU researcher suggests video games may not boost cognition 2Health News:Put down that Xbox remote: FSU researcher suggests video games may not boost cognition 3Health News:Breast Cancer Rates Jump Worldwide, Study Finds 2Health News:Breast Cancer Rates Jump Worldwide, Study Finds 3